Ponatinib | List of Frontiers open access articles

Original Research

Published on 06 Sep 2018

Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation

in Atherosclerosis and Vascular Medicine

Jesus Paez-Mayorga
Andrew L. Chen
Sivareddy Kotla
Yunting Tao
Rei J. Abe
Emma D. He
Brian P. Danysh
Marie-Claude C. Hofmann
Nhat-Tu Le

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2018.00125

8,603 views
37 citations

Original Research

Published on 07 Jan 2025

Ponatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagy

in Inflammation Pharmacology

Zhuomiao Lin
Meiqing Yang
Xihui Yu
Guozhu Tan
Jiahong Zhong

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1505768

2,625 views
1 citation

Original Research

Published on 16 Mar 2021

Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

in Hematologic Malignancies

Fausto Castagnetti
Fabrizio Pane
Gianantonio Rosti
Giuseppe Saglio
Massimo Breccia

Frontiers in Oncology

doi 10.3389/fonc.2021.642005

9,017 views
19 citations

Original Research

Published on 12 Jun 2018

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model

in Atherosclerosis and Vascular Medicine

Marianne G. Pouwer
Elsbet J. Pieterman
Lars Verschuren
Martien P. M. Caspers
Cornelis Kluft
Ricardo A. Garcia
Jurjan Aman
J. Wouter Jukema
Hans M. G. Princen

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2018.00055

11,146 views
65 citations

Original Research

Published on 15 Nov 2022

Ponatinib modulates the metabolic profile of obese mice by inhibiting adipose tissue macrophage inflammation

in Inflammation Pharmacology

Zhuomiao Lin
Xiaochun Lin
Ying Lai
Congcong Han
Xinran Fan
Jie Tang
Shiqi Mo
Jiahui Su
Sijia Liang
Jinyan Shang

Frontiers in Pharmacology

doi 10.3389/fphar.2022.1040999

5,582 views
7 citations

Original Research

Published on 12 Nov 2024

Chromatographic analysis of ponatinib and its impurities: method development, validation, and identification of new degradation product

in Analytical Chemistry

Jing Wang
Yonghong Zhu
Jisu Qin
Wenyi Wu
Rongrong Huang
Liangliang Cai

Frontiers in Chemistry

doi 10.3389/fchem.2024.1487108

2,626 views

Original Research

Published on 21 Jun 2019

Ponatinib Protects Mice From Lethal Influenza Infection by Suppressing Cytokine Storm

in Viral Immunology

Si Chen
Ge Liu
Jungang Chen
Ao Hu
Li Zhang
Wenyu Sun
Wei Tang
Chunlan Liu
Haiwei Zhang
Chang Ke

Frontiers in Immunology

doi 10.3389/fimmu.2019.01393

11,333 views
42 citations

Original Research

Published on 23 Sep 2024

Sustained antiviral response against in vitro HIV-1 infection in peripheral blood mononuclear cells from people with chronic myeloid leukemia treated with ponatinib

in Pharmacology of Infectious Diseases

Mario Manzanares
Fernando Ramos-Martín
Sara Rodríguez-Mora
Guiomar Casado-Fernández
Clara Sánchez-Menéndez
Alicia Simón-Rueda
Elena Mateos
Miguel Cervero
Adam M. Spivak
Vicente Planelles

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1426974

2,795 views
2 citations

Case Report

Published on 10 Jan 2023

Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia

in Hematologic Malignancies

Fabio Giglio
Edoardo Campodonico
Francesca Lorentino
Maddalena Noviello
Elisabetta Xue
Raffaella Greco
Lorenzo Lazzari
Alessandro Bruno
Maria Teresa Lupo Stanghellini
Matteo Giovanni Carrabba

Frontiers in Oncology

doi 10.3389/fonc.2022.1100105

4,086 views
2 citations

Original Research

Published on 03 Jul 2020

The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study

in Cardiovascular and Smooth Muscle Pharmacology

Hélène Haguet
Céline Bouvy
Anne-Sophie Delvigne
Elise Modaffari
Adeline Wannez
Pierre Sonveaux
Jean-Michel Dogné
Jonathan Douxfils

Frontiers in Pharmacology

doi 10.3389/fphar.2020.01007

8,990 views
31 citations

Systematic Review

Published on 20 Nov 2024

Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison

in Hematologic Malignancies

Valentin Garcia-Gutierrez
Fei Huang
Ajibade Ashaye
Mehul Dalal
Victor Laliman-Khara
Massimo Breccia
Megan Rutherford
Hoora Moradian
Petros Patos
Elias Joseph Jabbour

Frontiers in Oncology

doi 10.3389/fonc.2024.1455378

7,676 views
4 citations

Original Research

Published on 18 Oct 2021

Evaluation of CML TKI Induced Cardiovascular Toxicity and Development of Potential Rescue Strategies in a Zebrafish Model

in Predictive Toxicology

Shan Cheng
Pan Jin
Heying Li
Duanqing Pei
Xiaodong Shu

Frontiers in Pharmacology

doi 10.3389/fphar.2021.740529

7,442 views
11 citations

Case Report

Published on 18 Jun 2020

Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After Allogenic Stem Cell Transplant and Dasatinib: A Case Report

in Hematologic Malignancies

Cirino Botta
Nadia Caruso
Sabrina Bossio
Francesca Storino
Giuseppe Console
Massimo Martino
Francesco Mendicino
Eugenio Lucia
Rosellina Morelli
Pierpaolo Correale

Frontiers in Oncology

doi 10.3389/fonc.2020.00967

6,062 views
3 citations

Systematic Review

Published on 22 Sep 2021

Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis

in Pharmacology of Anti-Cancer Drugs

Olga Mulas
Giovanni Caocci
Brunella Mola
Giorgio La Nasa

Frontiers in Pharmacology

doi 10.3389/fphar.2021.674748

6,795 views
12 citations

Brief Research Report

Published on 02 Jul 2025

TNIK-driven regulation of ERK5 transcriptional activity in endothelial cells

in Cardiovascular Biologics and Regenerative Medicine

Venkata Subrahmanya Kumar Samanthapudi
Sivareddy Kotla
Nhat-Tu Le

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2025.1526676

3,916 views

Case Report

Published on 03 Nov 2023

Case report: Deep molecular remissions post two separate CD19-targeted chimeric antigen receptor T-cell therapies do not prevent disease from relapsing in Philadelphia chromosome-positive acute lymphoblastic leukemia

in Hematologic Malignancies

Yu Tang
Xiaoming Fei
Xianqiu Yu
Jiang Cao
Lixia Wang
Fang Lei

Frontiers in Oncology

doi 10.3389/fonc.2023.1251738

2,310 views

Articles

Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation

Ponatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagy

Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model

Ponatinib modulates the metabolic profile of obese mice by inhibiting adipose tissue macrophage inflammation

Chromatographic analysis of ponatinib and its impurities: method development, validation, and identification of new degradation product

Ponatinib Protects Mice From Lethal Influenza Infection by Suppressing Cytokine Storm

Sustained antiviral response against in vitro HIV-1 infection in peripheral blood mononuclear cells from people with chronic myeloid leukemia treated with ponatinib

Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia

The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study

Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison

Evaluation of CML TKI Induced Cardiovascular Toxicity and Development of Potential Rescue Strategies in a Zebrafish Model

Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After Allogenic Stem Cell Transplant and Dasatinib: A Case Report

Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis

TNIK-driven regulation of ERK5 transcriptional activity in endothelial cells

Case report: Deep molecular remissions post two separate CD19-targeted chimeric antigen receptor T-cell therapies do not prevent disease from relapsing in Philadelphia chromosome-positive acute lymphoblastic leukemia